Gene knockdown strategies

TH Takao Hikita
FM Fatemeh Mirzapourshafiyi
PB Pedro Barbacena
MR Meghan Riddell
AP Ayesha Pasha
ML Mengnan Li
TK Takuji Kawamura
RB Ralf P Brandes
TH Tomonori Hirose
SO Shigeo Ohno
HG Holger Gerhardt
MM Michiyuki Matsuda
CF Claudio A Franco
MN Masanori Nakayama
request Request a Protocol
ask Ask a question
Favorite

Oligonucleotide siRNA duplexes were purchased from GE Healthcare Dharmacon, Inc. Individual ON‐TARGETplus PARD3 (J‐015602‐05 5′‐AAGCAUGGAUUUAGGUAUA‐3′; J‐015602‐06 5′‐AGACUAAACUCAAUACAGU‐3′; J‐015602‐07 5′‐CGAUAAAGACAGACUGGUA‐3′; J‐015602‐08 5′‐GAUGGCGACCUUCGAAAUA‐3′) or scrambled control (D‐001810‐01 ON‐TARGETplus Non‐targeting siRNA#1, 5′‐UGGUUUACAUGUCGACUAA‐3′) was transfected into HUVECs using oligofectamine (12252011, Thermo Fisher) according to the manufacturer's instructions. Briefly, 4 × 100,000 HUVECs were seeded onto 60‐mm dish and cultured with growth medium (EGM‐2, 2% FBS) for 12 h. Thirty minutes before transfection, cells were washed once with PBS and incubated with Opti‐MEM. Scrambled or siPARD3s were diluted with Opti‐MEM, mixed with oligofectamine, and incubated for 30 min at room temperature. siRNA mixture was added onto the dish at final concentration of 100 nM, incubated for 6 h at 37°C, and added twice the volume of the growth medium containing 6% FBS (final concentration: 2% FBS). After 12 h, medium was changed to normal growth medium (2% FBS). Cells were analyzed 48 h post‐transfection. J‐015602‐08 and J‐015602‐06 were used in this study as siPAR‐3#1 and siPAR‐3#2, respectively.

Do you have any questions about this protocol?

Post your question to gather feedback from the community. We will also invite the authors of this article to respond.

post Post a Question
0 Q&A